AstraZeneca and RQ Biotechnology Sign License Agreement for Monoclonal Antibodies
AstraZeneca has signed a license agreement with RQ Biotechnology for monoclonal antibodies to treat COVID-19.
AstraZeneca has entered into a license agreement with RQ Biotechnology, a company focused on developing treatments and preventative therapies based on mAbs, for early-stage monoclonal antibodies (mAbs) targeted against COVID-19. Under the agreement, AstraZeneca will have an exclusive worldwide license to develop, manufacture, and commercialize mAbs.
RQ Biotechnology specifically focuses on addressing areas of unmet need in vulnerable patient populations through the use of potent broad-spectrum mAbs.
“The COVID-19 pandemic has changed the landscape for immune therapies, including the use of monoclonal antibodies to protect vulnerable patients who can’t respond adequately to vaccination alone,” said Iskra Reic, executive vice president, vaccine & immune therapies, AstraZeneca. “Scientific innovation is rapidly accelerating, and this agreement reflects our continued commitment to the discovery and development of new medicines to help prevent and treat infectious disease, including COVID-19.”
Source: AstraZeneca
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
